Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Yale University
The Methodist Hospital Research Institute
The Methodist Hospital Research Institute
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
The Methodist Hospital Research Institute
University of Texas Southwestern Medical Center
Cedars-Sinai Medical Center
Montefiore Medical Center
Weill Medical College of Cornell University
Providence Health & Services
SCRI Development Innovations, LLC
Consorzio Oncotech
University of Chicago
University of Alabama at Birmingham
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
Hellenic Cooperative Oncology Group